Prostrakan and AstraZeneca enter into agreement for rights to Moventig® in Europe
Moventig is the first once-daily, oral peripherally acting mu-opioid receptor antagonist approved in Europe for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s)
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Legislation & regulation Gastroenterology Oncology Pain management Patient care Latest News laxatives moventig naloxegol oic opioid induced constipation PAMORA Source Type: news
More News: AstraZeneca | Cancer & Oncology | Constipation | Drugs & Pharmacology | Gastroenterology | Pain | Pain Management